Cart
sales@molnova.com
Erythromycin estolate
CAS No. 3521-62-8
Erythromycin estolate( —— )
Catalog No. M33353 CAS No. 3521-62-8
Erythromycin estolate
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 35 | In Stock |
|
| 50MG | 31 | In Stock |
|
| 100MG | 45 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 111 | In Stock |
|
| 1G | 163 | In Stock |
|
Biological Information
-
Product NameErythromycin estolate
-
NoteResearch use only, not for human use.
-
Brief DescriptionErythromycin estolate
-
DescriptionErythromycin estolate, erythromycin derivative, is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetAntibacterial
-
RecptorAntibacterial
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3521-62-8
-
Formula Weight1056.39
-
Molecular FormulaC52H97NO18S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (94.66 mM; Ultrasonic )
-
SMILESCCCCCCCCCCCCOS(O)(=O)=O.CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(C2OC(=O)CC)N(C)C)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Cefathiamidine
Cefathiamidine??exhibits a wide spectrum of antimicrobial activity against bacteria.?Cefathiamidine is used for the treatment of respiratory liver five senses urinary tract infections endocarditis and sepsis.
-
Ethyl acetoacetate
Ethyl acetoacetate (Ethyl acetylacetate), an ester, is a bacterial biofilm inhibitor and an intermediate utilized in the synthesis of various compounds.
-
PBP 10
Selective formyl peptide receptor 2 (FPR2) antagonist; cell permeable. Selectively inhibits FPR2-mediated NADPH oxidase activity but has no effect on FPR1 signaling in neutrophils. Displays PIP2 binding activity in vitro and blocks cell motility. Also exhibits antiviral activity against influenza viruses via inhibition of viral-induced ERK activation.
